# Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07637513/  
OnCo record `nct07637513` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tarlatamab and durvalumab in lung cancer, run by PrECOG, LLC., not yet recruiting.

## Summary

Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT07637513 by PrECOG, LLC., with a registry enrolment figure of 430 participants, started 2027-01 and due to reach its primary completion in 2037-11. Interventions recorded: Tarlatamab; Durvalumab. Conditions listed: Limited Stage Small-Cell Lung Cancer. Primary outcome: This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).; This phase III study has dual primary endpoints of progression-free survival (PFS) and overall survival (OS).. Lung eligibility wording from the registry: "* Patient must have histologically or cytologically confirmed Small Cell Lung Cancer (SCLC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: PrE0512
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07637513
- Phase: 3
- Setting: Phase III Trial of Consolidation Tarlatamab + Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC)
- Sponsor: PrECOG, LLC.
- Enrolled: 430

## Sources

- ClinicalTrials.gov NCT07637513: https://clinicaltrials.gov/study/NCT07637513

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Tarlatamab](https://onco.cc/drugs/tarlatamab/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07637513.json